Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Increases By 7,658.5%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large increase in short interest in July. As of July 15th, there was short interest totaling 473,657 shares, an increase of 7,658.5% from the June 30th total of 6,105 shares. Based on an average trading volume of 2,079,462 shares, the days-to-cover ratio is currently 0.2 days. Currently, 7.8% of the company’s stock are short sold.

Institutional Investors Weigh In On Matinas Biopharma

A hedge fund recently bought a new position in Matinas Biopharma stock. DRW Securities LLC purchased a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma as of its most recent filing with the SEC. 11.77% of the stock is currently owned by institutional investors.

Matinas Biopharma Stock Down 3.1%

Shares of MTNB traded down $0.01 during trading hours on Friday, reaching $0.24. The company’s stock had a trading volume of 21,013,035 shares, compared to its average volume of 393,812. The company has a 50 day moving average of $0.63 and a two-hundred day moving average of $0.62. The firm has a market cap of $1.55 million, a price-to-earnings ratio of -0.12 and a beta of 1.71. Matinas Biopharma has a 1-year low of $0.23 and a 1-year high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.30) earnings per share for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.